Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

382
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeted attenuation of liver fibrosis using microbubble-enhanced protease-activated receptor 1 chimeric antigen receptor T cells.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Association between antihypertensive medications and hepatocellular carcinoma risk in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) without cirrhosis.

Annals of hepatology·2026
Same author

Dendritic Cell Served as Salvage Therapy for Advanced Hepatocellular Carcinoma Resistant to Tyrosine Kinase or Immune Checkpoint Inhibitors.

Cancers·2026
Same author

Outcomes of Liver Transplantation Without Alcohol Abstinence in Alcohol-Associated Hepatitis With Original MELD Score ≥30.

Annals of transplantation·2026
Same author

Intensity-modulated proton therapy for patients with unresectable giant (≥ 10 cm) hepatocellular carcinoma: a retrospective analysis from two high-volume centers.

Japanese journal of radiology·2026
Same author

Proton Radiotherapy Alone versus Combined with Immunotherapies or Tyrosine Kinase Inhibitors for Barcelona Clinic Liver Cancer Stage B or C Hepatocellular Carcinoma.

Liver cancer·2026

Related Experiment Video

Updated: May 4, 2026

Application of Hemostatic Devices in Laparoscopic Hepatectomy
04:23

Application of Hemostatic Devices in Laparoscopic Hepatectomy

Published on: April 19, 2022

2.1K

Does very high alpha-fetoprotein affect very early hepatocellular carcinoma receiving hepatectomy?

Hong-Shiue Chou1,2, Chen-Fang Lee1,2, Hao-Chien Hung3,4

  • 1Division of Liver and Transplantation Surgery, Chang-Gung Memorial Hospital, Taoyuan, Taiwan.

Langenbeck'S Archives of Surgery
|April 9, 2025
PubMed
Summary
This summary is machine-generated.

High alpha-fetoprotein (AFP) levels do not impact survival in early-stage hepatocellular carcinoma (HCC) patients after liver resection. Curative treatment should be prioritized regardless of AFP levels for these HCC patients.

Keywords:
Alpha-fetoprotein (AFP)Disease-free survival (DFS)Hepatocellular carcinoma (HCC)Overall survival (OS)Partial liver resection

More Related Videos

Laparoscopic Anterior Right Hepatectomy: A Single-Center Experience
09:51

Laparoscopic Anterior Right Hepatectomy: A Single-Center Experience

Published on: December 4, 2023

957
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

357

Related Experiment Videos

Last Updated: May 4, 2026

Application of Hemostatic Devices in Laparoscopic Hepatectomy
04:23

Application of Hemostatic Devices in Laparoscopic Hepatectomy

Published on: April 19, 2022

2.1K
Laparoscopic Anterior Right Hepatectomy: A Single-Center Experience
09:51

Laparoscopic Anterior Right Hepatectomy: A Single-Center Experience

Published on: December 4, 2023

957
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

357

Area of Science:

  • Hepatocellular Carcinoma Research
  • Surgical Oncology
  • Biomarker Analysis

Background:

  • Recurrence after liver resection (LR) significantly impacts hepatocellular carcinoma (HCC) prognosis.
  • Elevated alpha-fetoprotein (AFP) is often linked to poor outcomes and recurrence in HCC patients.
  • Investigating the prognostic value of high AFP (>1,000 ng/ml) in early-stage HCC (BCLC stage 0) post-LR is crucial.

Purpose of the Study:

  • To evaluate the impact of high AFP levels on survival outcomes in BCLC stage 0 HCC patients undergoing LR.
  • To identify clinicopathologic factors influencing survival and recurrence in this patient cohort.

Main Methods:

  • Retrospective analysis of 223 BCLC stage 0 HCC patients who underwent LR between 2004 and 2012.
  • Comparison of outcomes between patients with low AFP (n=200) and high AFP (n=23) using statistical analyses (chi-square, t-test, Cox regression, Kaplan-Meier).
  • Assessment of associations between clinicopathologic variables (tumor size, capsule, cirrhosis, HAI, microvascular invasion) and survival.

Main Results:

  • No significant difference in disease-free survival (DFS) or overall survival (OS) between low and high AFP groups (p > 0.05).
  • Clinicopathologic features were similar between the groups.
  • HCC recurrence was associated with ICG R15, HAI score, and cirrhosis, but not AFP levels.

Conclusions:

  • AFP levels should not influence the timing of curative-intent therapy for BCLC stage 0 HCC patients post-LR.
  • Early consideration of curative treatment is recommended for all stage 0 HCC patients undergoing LR, irrespective of preoperative AFP levels.